within Pharmacolibrary.Drugs.ATC.B;

model B02BX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 3.04 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,
    adminCount     = 1,
    Vd             = 0.00186,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014466666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that stimulates platelet production by binding to and activating the thrombopoietin receptor (c-Mpl). It is approved for the treatment of chronic immune (idiopathic) thrombocytopenia purpura (ITP) in adult patients who are refractory to other treatments such as corticosteroids, immunoglobulins, or splenectomy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with chronic ITP, as described in clinical trials and modeling reports. Typically, a two-compartment model with subcutaneous administration is used. Parameters reflect mean estimates across adult patient populations.</p><h4>References</h4><ol><li><p>Frampton, JE, &amp; Lyseng-Williamson, KA (2009). Romiplostim. <i>Drugs</i> 69(3) 307–317. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200969030-00006&quot;>10.2165/00003495-200969030-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19275274/&quot;>https://pubmed.ncbi.nlm.nih.gov/19275274</a></p></li><li><p>Makarenko, I, et al., &amp; Drai, R (2023). A randomized, double-blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers. <i>Pharmacology research &amp; perspectives</i> 11(5) e01125–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.1125&quot;>10.1002/prp2.1125</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37740581/&quot;>https://pubmed.ncbi.nlm.nih.gov/37740581</a></p></li><li><p>Perreault, S, &amp; Burzynski, J (2009). Romiplostim: a novel thrombopoiesis-stimulating agent. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 66(9) 817–824. DOI:<a href=&quot;https://doi.org/10.2146/ajhp080524&quot;>10.2146/ajhp080524</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19386944/&quot;>https://pubmed.ncbi.nlm.nih.gov/19386944</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02BX04;
